PPROM at 29 Weeks with Previous LSCS

Diagnosis & Initial Assessment

• Sterile speculum examination (avoid digital vaginal examination — shortens latent period, increases infection risk)
• Nitrazine/pH test: amniotic fluid pH 7.0–7.4 (turns nitrazine dark blue)
• Ferning on microscopy
• Pooling of fluid in posterior fornix
• If equivocal: placental alpha-microglobulin-1 (PAMG-1/AmniSure) or IGFBP-1 test (high sensitivity)
• Ultrasound: oligohydramnios supports but does not confirm diagnosis

Significance of Previous LSCS

1. Uterine scar dehiscence/rupture risk — while rare in expectant management, the weakened lower segment must be monitored
2. Route of delivery — if delivery is needed, prior LSCS influences decision (see below)
3. Placenta praevia/accreta spectrum — must be excluded on ultrasound (higher risk with prior LSCS + PPROM)
4. Tocolysis — brief tocolysis is relatively safe with prior LSCS for short-term steroid completion, but prolonged tocolysis in the context of prior LSCS and PPROM carries risk
5. Chorioamnionitis is the most dangerous complication — with a uterine scar, maternal sepsis and rupture risk compound each other

Principles of Management (29 Weeks)

1. Admission & Monitoring

• Inpatient at a tertiary centre with level III NICU
• Daily maternal observations: temperature, pulse, uterine tenderness
• Serial WBC/CRP (every 48–72 h)
• CTG daily (twice daily if concerns)
• Ultrasound assessment every 1–2 weeks (growth, AFI, Dopplers)
• Fetal movements monitoring

2. Corticosteroids (MANDATORY)

• Betamethasone 12 mg IM × 2 doses, 24 hours apart (or dexamethasone 6 mg × 4 doses, 12 hours apart)
• Dramatically reduces RDS, IVH, NEC
• Should not be withheld due to previous LSCS
• Rescue course may be considered if >2 weeks have elapsed and delivery appears imminent before 34 weeks

3. Antibiotics

• Erythromycin 250 mg PO QDS × 10 days (first-line per ORACLE I trial — reduces neonatal morbidity, prolongs latency)
• Alternatively: co-amoxiclav is avoided (ORACLE trial: associated with increased NEC)
• If GBS positive or signs of infection: add appropriate cover (e.g., IV benzylpenicillin for GBS intrapartum prophylaxis)
• Some guidelines use: Azithromycin + Amoxicillin (ACOG regimen: IV ampicillin + azithromycin × 48h, then oral amoxicillin + azithromycin × 5 days)

4. Magnesium Sulfate (Neuroprotection)

• MgSO₄ 4 g IV loading dose then 1 g/hour for fetal neuroprotection
• Given when delivery is imminent at <32 weeks (reduces risk of cerebral palsy by ~30%)
• At 29 weeks with threatened preterm delivery, this should be initiated promptly

5. Tocolysis

• Short-term tocolysis (24–48 hours) may be considered ONLY to:
  • Allow corticosteroids to take effect
  • Facilitate in-utero transfer to tertiary centre
• NOT recommended for prolonged use in PPROM — increases infection risk without proven benefit
• Previous LSCS is not an absolute contraindication to tocolysis, but uterine activity must be monitored carefully
• Agents: nifedipine or atosiban preferred; avoid NSAIDs at this gestational age (risk of premature ductus closure)

6. Timing & Mode of Delivery

• Caesarean section is NOT automatically indicated purely because of prior LSCS
• If the fetus is cephalic and there are no other contraindications: VBAC (vaginal birth after caesarean) is a reasonable option, but scar integrity and labour progress must be monitored closely
• If the fetus is breech/transverse (common at 29 weeks) → Elective LSCS
• If there are signs of chorioamnionitis or emergency: Emergency LSCS
• At 29 weeks, many fetuses will be non-cephalic → LSCS is frequently the route

Contraindications to Conservative Management (Delivery Indicated)

• Chorioamnionitis (fever >38°C, uterine tenderness, fetal tachycardia, offensive discharge, raised WBC/CRP)
• Non-reassuring CTG / fetal distress
• Cord prolapse
• Placental abruption
• Active labour not arrested

Summary Management Algorithm

PPROM at 29 weeks + prior LSCS
         ↓
Confirm diagnosis (speculum, nitrazine, ferning)
         ↓
Exclude complications: chorioamnionitis, cord prolapse, abruption
         ↓
         ├─ Complication present → Deliver (LSCS if breech/non-cephalic or emergency)
         │
         └─ No complication → Expectant management
               ├─ Betamethasone × 2 doses
               ├─ Erythromycin 10 days
               ├─ MgSO₄ if delivery imminent (<32 wk)
               ├─ Inpatient monitoring (CTG, obs, bloods)
               ├─ Serial USS (growth, AFI, Dopplers)
               └─ Deliver at 34 weeks OR earlier if complications arise

Key Points Specific to Prior LSCS

• Monitor for scar dehiscence (lower abdominal pain, scar tenderness)
• Assess placental site carefully (accreta spectrum with prior LSCS)
• If repeat LSCS planned, involve senior/consultant team; prepare for possible scar complications
• Counsel patient regarding both VBAC and elective LSCS options if she progresses toward delivery

• Tintinalli's Emergency Medicine: A Comprehensive Study, Chapter 100 (PPROM section)
• Creasy & Resnik's Maternal-Fetal Medicine: Principles and Practice (PPROM and preterm birth chapters)
• Giouleka S et al. Diagnosis and Management of PPROM: A Comprehensive Review of Major Guidelines. Obstet Gynecol Surv. 2024 — comparing ACOG, RCOG, and SOGC guidelines [PMID: 39437377]
• SMFM Consult Series #71: Management of previable and periviable PPROM. AJOG 2024 [PMID: 39025459]